Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach
A general subsidy in both settings is a clean result for Roche’s subcutaneous strategy, landing before pertuzumab biosimilars.
Breast Cancer
Tuznue Won Brazil Approval a Month After Its Plant Passed Anvisa Inspection, Nearly 20 Months After Filing
In Brazil the constraint on Prestige’s Herceptin biosimilar was not the dossier. It was the factory inspection.
Lilly’s New Combination Beats its Own Monotherapy
Median PFS doubled to 11.1 months against Inluriyo alone. The comparison payers will run is not in the package.
NICE Reversed on Enhertu Because the Threshold Moved, Not the Evidence
The clinical evidence did not change. NICE’s cost-effectiveness threshold did, as a term of a bilateral trade agreement.
Canada Moved Two Cancer Drugs Forward in One Week. Neither Went the Normal Route.
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial
The reimbursement case is being built before the product exists. Two gates remain, and a guideline solves neither.
ADCs Graduated From Salvage to First Line, Twice in a Week
Enhertu with pertuzumab and Trodelvy with Keytruda both won CHMP opinions for first-line metastatic breast cancer, moving ADCs from last resort to standard.
Stratipath And Roche Collaborate To Expand Access To Ai-powered Breast Cancer Diagnostics
Stratipath, a leader in AI-based precision diagnostic solutions, has announced a collaboration with Roche, the world’s largest biotechnology company and a global leader in in-vitro diagnostics. Through this partnership, Roche gains distribution rights to Stratipath’s AI-driven diagnostic tool, Stratipath Breast. This solution integrates seamlessly with Roche’s navify® Digital Pathology enterprise software, allowing users to perform … Read more